XOMA Royalty Corp XOMAO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-11.82
Altman Z″ — distress risk · distress
17.3%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $10.3M | $31.7M | — | — | $83.9M |
| 2024 | $6.7M | -$13.8M | — | -$13.8M | $61.9M |
| 2023 | $2.6M | -$40.8M | — | -$18.2M | $68.7M |
| 2022 | $6.0M | -$17.1M | — | — | $124.0M |
| 2021 | $38.2M | $15.8M | — | — | $141.9M |
| 2020 | $29.4M | $13.3M | — | $10.1M | $86.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | director | 2026-05-21 | Grant | 3,586 | — |
| LIMBER JOSEPH M | director | 2026-05-21 | Grant | 3,586 | — |
| Hernday Natasha | director | 2026-05-21 | Grant | 3,586 | — |
| PERRY MATTHEW D | director | 2026-05-21 | Grant | 3,586 | — |
| Franklin Heather L | director | 2026-05-21 | Grant | 3,586 | — |
| Kosacz Barbara | director | 2026-05-21 | Grant | 3,586 | — |
| BVF PARTNERS L P/IL | 10% owner | 2026-05-14 | Conversion | 2,313,000 | $4.03 |
| BVF PARTNERS L P/IL | 10% owner | 2026-05-14 | Conversion | 1,506,000 | $4.03 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.82 (distress)
- Working capital / assets 0.302
- Retained earnings / assets -4.479
- EBIT / assets 0.042
- Equity / liabilities 0.497
Source: SEC EDGAR filings · CIK 0000791908 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.